Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

radiotherapy

- PMLiVE

Pfizer’s PADCEV gets FDA approval for bladder cancer

Bladder cancer affects more than 614,000 people globally each year

- PMLiVE

Johnson & Johnson’s TAR-200 granted FDA priority review to treat bladder cancer

An estimated 84,870 people will be diagnosed with bladder cancer in the US this year

- PMLiVE

AstraZeneca’s Imfinzi regimen approved by EC to treat muscle-invasive bladder cancer

More than 35,000 people in five major European countries were treated for the disease last year

- PMLiVE

AstraZeneca receives CHMP recommendation for Imfinzi regimen in bladder cancer

More than 614,000 cases of bladder cancer are diagnosed globally every year

- PMLiVE

Johnson & Johnson’s bladder cancer therapy Balversa accepted by SMC

Almost 1,700 people are diagnosed with bladder cancer in Scotland annually

- PMLiVE

AstraZeneca announces positive phase 3 results for Imfinzi in high-risk bladder cancer

Around half of NMIBC patients are classed as being high-risk for disease progression or recurrence

- PMLiVE

Pfizer’s sasanlimab improves event-free survival in phase 3 bladder cancer trial

As many as half of patients with high-risk NMIBC experience disease recurrence despite BCG treatment

- PMLiVE

AstraZeneca’s Imfinzi regimen approved by FDA to treat bladder cancer

Around half of patients who undergo bladder removal surgery experience disease recurrence

- PMLiVE

AstraZeneca shares promising phase 3 results for Imfinzi in bladder cancer

More than 614,000 people are diagnosed with bladder cancer globally every year

- PMLiVE

Pfizer/Astellas share positive phase 3 results for Padcev in bladder cancer

Approximately 614,000 people are diagnosed with bladder cancer globally every year

- PMLiVE

ICR researchers uncover new method for predicting bowel cancer risk in IBD patients

Approximately 500,000 people in the UK are affected by Crohn’s disease or ulcerative colitis

- PMLiVE

ICR researchers uncover genes responsible for tumour progression in prostate cancer

The findings could pave the way for new treatment approaches that improve patient outcomes

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links